130 related articles for article (PubMed ID: 9614864)
1. Lamivudine therapy of WHV-infected woodchucks.
Mason WS; Cullen J; Moraleda G; Saputelli J; Aldrich CE; Miller DS; Tennant B; Frick L; Averett D; Condreay LD; Jilbert AR
Virology; 1998 May; 245(1):18-32. PubMed ID: 9614864
[TBL] [Abstract][Full Text] [Related]
2. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.
Yuen MF; Wong DK; Sum SS; Yuan HJ; Yuen JC; Chan AO; Wong BC; Lai CL
Am J Gastroenterol; 2005 May; 100(5):1099-103. PubMed ID: 15842584
[TBL] [Abstract][Full Text] [Related]
3. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
4. Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks.
Lu M; Hilken G; Yang D; Kemper T; Roggendorf M
J Virol; 2001 Apr; 75(8):3811-8. PubMed ID: 11264370
[TBL] [Abstract][Full Text] [Related]
5. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
7. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections.
Zhou T; Guo JT; Nunes FA; Molnar-Kimber KL; Wilson JM; Aldrich CE; Saputelli J; Litwin S; Condreay LD; Seeger C; Mason WS
J Virol; 2000 Dec; 74(24):11754-63. PubMed ID: 11090175
[TBL] [Abstract][Full Text] [Related]
9. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
Wolters LM; van Nunen AB; Niesters HG; de Man RA
Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
[TBL] [Abstract][Full Text] [Related]
10. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
Tsubota A
J Gastroenterol Hepatol; 2006 Dec; 21(12):1769-71. PubMed ID: 17074012
[No Abstract] [Full Text] [Related]
11. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks.
Korba BE; Cote P; Hornbuckle W; Schinazi R; Gangemi JD; Tennant BC; Gerin JL
Antivir Ther; 2000 Jun; 5(2):95-104. PubMed ID: 10971862
[TBL] [Abstract][Full Text] [Related]
12. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Le Guerhier F; Pichoud C; Jamard C; Guerret S; Chevallier M; Peyrol S; Hantz O; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2001 Apr; 45(4):1065-77. PubMed ID: 11257017
[TBL] [Abstract][Full Text] [Related]
14. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
15. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
16. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
17. Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine.
D'Ugo E; Kondili LA; Canitano A; Catone S; Giuseppetti R; Gallinella B; Palmieri G; Orobello S; Argentini C; Glück R; Rapicetta M
Vaccine; 2007 Jun; 25(26):4895-902. PubMed ID: 17531355
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
Fischer KP; Gutfreund KS; Tyrrell DL
Drug Resist Updat; 2001 Apr; 4(2):118-28. PubMed ID: 11512520
[TBL] [Abstract][Full Text] [Related]
19. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
20. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
